共 44 条
- [31] The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence:: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patientsINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (05): : 653 - 660Bender, StefanScherbaum, NorbertSoyka, MichaelRuether, EckartMann, KarlGastpar, Markus
- [32] J-FORCE study: A randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based, highly emetogenic chemotherapyANNALS OF ONCOLOGY, 2017, 28Hashimoto, H.Iwasa, S.Abe, M.Yanai, T.Zenda, S.Yamaguchi, T.Kaba, H.Fukuda, H.Terakado, H.Ohe, Y.
- [33] A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) StudyCANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 90 - 97Jeon, So-YeonHan, Hye SookBae, Woo KyunPark, Moo-RimShim, HyeokLee, Sang-CheolGo, Se-IlYun, Hwan JungIm, Yong-JinSong, Eun-Kee
- [34] Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority studyLANCET ONCOLOGY, 2016, 17 (03): : 332 - 344Kovacs, GaborWachtel, Antonio E.Basharova, Elena V.Spinelli, TullaNicolas, PierreKabickova, Edita
- [35] Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Hashimoto, HironobuYamanaka, TakeharuShimada, YasuhiroArata, KojiMatsui, ReikoGoto, KoichiTakiguchi, TomomiOhyanagi, FumiyoshiKogure, YukiNogami, NaoyukiNakao, MasahikoTakeda, KojiAzuma, KanakoNagase, SeisukeHayashi, ToshinobuFujiwara, KimikoShimada, ToshikazuSeki, NobuhikoSuzuki, KenichiYamamoto, Nobuyuki
- [36] A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy- induced nausea and vomiting (OFFER study)ECLINICALMEDICINE, 2023, 55Zhao, YuanyuanYang, YunpengGao, FangfangHu, ChangluZhong, DianshengLu, MiaozhenYuan, ZhipingZhao, JianqingMiao, JidongLi, YanZhu, JieWang, ChunbinHan, JianjunZhao, YanqiuHuang, YanZhang, Li
- [37] Olanzapine versus fosaprepitant for prevention of chemotherapy induced nausea and vomiting in patients receiving carboplatin (AUC ≥ 4) containing chemotherapy regimen: A phase 3 randomized, double-blind, placebo-controlled trialJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Bhargave, SnehKumar, AkashSharma, VinodKataria, BabitaPushpam, DeepamBatra, AtulPramanik, RajaKhurana, SachinSahoo, Ranjit KumarMalik, Prabhat SinghBakhshi, SameerSharma, AtulKumar, Lalit
- [38] Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY, 2020, 21 (02): : 242 - 249Hashimoto, HironobuAbe, MasakazuTokuyama, OsamuMizutani, HideakiUchitomi, YosukeYamaguchi, TakuhiroHoshina, YukariSakata, YasuhikoTakahashi, Takako YanaiNakashima, KazuhisaNakao, MasahikoTakei, DaisukeZenda, SadamotoMizukami, KokiIwasa, SatoruSakurai, MichiruYamamoto, NoboruOhe, Yuichiro
- [39] A randomized, double-blind, placebo-controlled phase Ill trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Hashimoto, HironobuAbe, MasakazuNakao, MasahikoMizutani, HideakiSakata, YasuhikoFujita, YukiyoshiNishimura, TomoyasuHirano, KatsuyaOkada, HideakiInui, NaokiSakata, YukioIihara, HirotoshiZenda, SadamotoUchitomi, YosukeYamaguchi, TakuhiroHoshina, YukariYanai, TakakoIwasa, SatoruYamamoto, NoboruOhe, Yuichiro
- [40] Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trialLANCET RESPIRATORY MEDICINE, 2016, 4 (09): : 699 - 707Gonem, SherifBerair, RachidSingapuri, AmishaHartley, RuthLaurencin, Marie F. M.Bacher, GeraldHolzhauer, BjornBourne, MichelleMistry, VijayPavord, Ian D.Mansur, Adel H.Wardlaw, Andrew J.Siddiqui, Salman H.Kay, Richard A.Brightling, Christopher E.